Special Issue

Psychiatry: Biomarkers, Genetics and Treatment Strategies

Message from the Guest Editors

Currently, recent advances in genetics and genomics provide insights into the genetic basis of psychiatry. Understanding fundamental regulatory mechanisms such as signaling pathways, high-dimensional chromatin structure, epigenetic modifications, and transcription factors has become critical for identifying new therapeutic targets in psychiatry. Furthermore, a deeper understanding of how these regulatory processes affect gene expression could provide new avenues for the development of targeted treatments for psychiatric disorders. Therefore, a better understanding of genomic regulation and mechanisms in psychiatry has become crucial for psychiatric prediction, diagnosis, and treatment. Additionally, the combination of biomarkers with computational psychiatry and machine learning for predictive analytics will be a key factor driving the field forward. So if future research is promising to develop potential biomarkers of psychiatric disorders to help determine the prediction, diagnosis, and staging of psychiatric disorders, it is also crucial for every patient suffering from psychiatric disorders.

Guest Editors

Prof. Dr. Anamaria Ciubara

Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, Galați, Romania

Prof. Dr. Michael Davidson

University of Nicosia Medical School, Nicosia, Cyprus

Deadline for manuscript submissions

closed (5 February 2024)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/181077

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI